Dr. Perry has extensive experience in preclinical and clinical drug development. He is a venture capitalist currently with Bioscience Managers, a global venture capital firm, and previously with Bay City Capital LLC (2005-2012). Dr. Perry also currently serves as faculty at Houston Methodist and he is Adjunct Professor at the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus.
Dr. Perry has served in various pharmaceutical executive positions. From 2017 to 2022 he was CEO of Avita Medical, Inc., a regenerative medicine company based in Valencia, CA. From 1994-2000 and 2012-2017, he had various executive positions within Novartis, the US affiliate of Switzerland-based Novartis AG, a global pharmaceutical company. He served as CSO of Novartis’ Cell and Gene Therapy Unit (2014 to 2017); VP and Global Head of Stem Cell Therapy (2012 to 2014); President and CEO of both SyStemix Inc. and Genetic Therapy Inc., two wholly owned subsidiaries of Novartis Corp. (1997 to 2000), and VP of Regulatory Affairs for Novartis Pharma (previously Sandoz Pharmaceuticals, 1994-1997). Dr. Perry held various organizational leadership positions with various other companies from 2000-2012.
Dr. Perry serves on the Scientific Advisory Board of 7 Hills Pharma, a private clinical-stage pharmaceutical company; and is Chair of the Translational Medicine Advisory Board of the Houston Methodist Research Institute. He has also been on the board of 10 other companies.
Dr. Perry holds an Honors BS (Physics and Engineering) and a PhD (Biomedical Pharmacology) from the University of Guelph, Ontario, Canada. He has also earned a DVM (Doctor of Veterinary Medicine & Surgery) from Ontario Veterinary College and he is a graduate of the International Advanced Management Program at Harvard Business School.
What is Michael S. Perry's net worth?
The estimated net worth of Michael S. Perry is at least $7.75 million as of December 5th, 2025. Perry owns 115,240 shares of Arrowhead Pharmaceuticals stock worth more than $7,748,161 as of January 13th. This net worth estimate does not reflect any other assets that Perry may own. Learn More about Michael S. Perry's net worth.
How do I contact Michael S. Perry?
Has Michael S. Perry been buying or selling shares of Arrowhead Pharmaceuticals?
Michael S. Perry has not been actively trading shares of Arrowhead Pharmaceuticals over the course of the past ninety days. Most recently, Michael S. Perry sold 16,250 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $61.03, for a transaction totalling $991,737.50. Following the completion of the sale, the director now directly owns 115,240 shares of the company's stock, valued at $7,033,097.20. Learn More on Michael S. Perry's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?
Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Hongbo Lu (Director), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Michael Perry (Director), Javier San Martin (Insider), Victoria Vakiener (Director), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?
In the last year, insiders at the biotechnology company sold shares 25 times. They sold a total of 847,675 shares worth more than $39,382,236.43. The most recent insider tranaction occured on January, 5th when COO Patrick O'brien sold 49,493 shares worth more than $3,123,503.23. Insiders at Arrowhead Pharmaceuticals own 4.3% of the company.
Learn More about insider trades at Arrowhead Pharmaceuticals. Information on this page was last updated on 1/5/2026.
